Leadership Team - Trovagene

Leadership Team

Working to develop oncology therapeutics to improve cancer care

Leadership Team

Trovagene is a clinical-stage oncology therapeutics company. Our primary focus is to develop targeted therapeutics for improved cancer care utilizing our expertise and technology in tumor genomics and biomarkers to optimize drug development and to help identify patients most likely to respond. Our dedicated team give their time and energy for something they truly value and in turn we are striving to develop new cancer therapeutics in areas of significant medical need, such as Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and metastatic Colorectal Cancer (mCRC). It is through our passion and desire to transform cancer care that we have embarked on a journey to develop our lead drug candidate, onvansertib, a first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1 (PLK1) Inhibitor currently in clinical development to treat leukemias, lymphomas and solid tumor cancers.

Board of Directors

Thomas H. Adams, Ph.D.

Chief Executive Officer and Chairman